Skip Navigation

Rheumatology 2005 44(10):1205-1206; doi:10.1093/rheumatology/kei103
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ledingham, J.
Right arrow Articles by Deighton, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ledingham, J.
Right arrow Articles by Deighton, C.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

EDITORIAL

British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments

J. Ledingham, C. Wilkinson1 and C. Deighton1

Rheumatology Department, Queen Alexandra Hospital, Cosham, Portsmouth and 1 Rheumatology Department, Derbyshire Royal Infirmary, Derby, UK

Correspondence to: J. M. Ledingham, Rheumatology Department, Queen Alexandra Hospital, Cosham, Portsmouth PO6 3LY, UK. E-mail: jo.ledingham@portshosp.nhs.uk

The first 150 words of the full text of this article appear below.

Anti-TNF drugs have revolutionized rheumatology practice. However, these new drugs have also created new problems that UK rheumatologists have rarely had to consider in their patients. In particular, a major concern is the propensity of patients on anti-TNF therapy to develop reactivation of latent tuberculosis (TB). A recent review in this journal has highlighted these problems [1]. The increase in TB associated with anti-TNF-{alpha} therapy is well documented for all three available anti-TNF drugs [2–4] and has resulted in manufacturers recommending tuberculin skin testing and other screening procedures for TB prior to commencing treatment. The British Society for Rheumatology (BSR) and the British Society for Gastroenterology have worked with the British Thoracic Society (BTS) in drawing up recommendations for: (i) assessing the risk of TB infection in patients due to start anti-TNF therapy, and (ii) the management of any TB infection present in patients either due . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
B. SOBORG, M. RUHWALD, M. L. HETLAND, S. JACOBSEN, A. B. ANDERSEN, N. MILMAN, V. O. THOMSEN, D. V. JENSEN, A. KOCH, J. WOHLFAHRT, et al.
Comparison of Screening Procedures for Mycobacterium tuberculosis Infection Among Patients with Inflammatory Diseases
J Rheumatol, September 1, 2009; 36(9): 1876 - 1884.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. M. Fremond, D. Togbe, E. Doz, S. Rose, V. Vasseur, I. Maillet, M. Jacobs, B. Ryffel, and V. F. J. Quesniaux
IL-1 Receptor-Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to Mycobacterium tuberculosis Infection
J. Immunol., July 15, 2007; 179(2): 1178 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. J. Kay, I. D. Griffiths, and for the BSR Biologics Register Management committe
UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register
Rheumatology, November 1, 2006; 45(11): 1376 - 1379.
[Abstract] [Full Text] [PDF]